FDA grants Fast Track designation to losmapimod for potential treatment of facioscapulohumeral muscular dystrophy (FSHD)

Losmapimod is a selective p38α/β mitogen activated protein kinase inhibitor which has been evaluated in more than 3600 subjects in clinical trials across FSHD and multiple other indications. There are currently no approved therapies to treat patients with FSHD.

Source:

Biospace Inc.